Clinical trials: Illness, Chronic
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
The primary objective of this study is to compare the pharmacokinetic (PK) and pharmacodynamics (PD) of single subcutaneous (SC) and intramuscular (IM) doses of 300 mg natalizumab to intravenous (IV) administration of 300 mg…
- Trial name
- NCT00559702
- Testing
- natalizumab, standard of care
- Where
- 12 sites in United States
- Volunteers
- 76 people
- Sponsor
- Biogen
Multiple Chronic Diseases
Multiple Chronic Diseases: the RITH Trial
In this research, investigators pretent to evaluate the effectiveness of clinical, functional, psychological and social impact of an intervention model based on shared care between the Mobile Rehabilitation and Physical therapy…
- Trial name
- NCT02715245
- Testing
- Home-based rehabilitation
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Universidad de Almeria
Chronic Obstructive Pulmonary Disease
Rethinking Pulmonary Rehabilitation - a Three-arm Randomised Multicentre Trial
Pulmonary rehabilitation (PR) is one of the cornerstones of care for people with COPD together with smoking cessation and medical treatment.
- Trial name
- REPORT (NCT05664945)
- Testing
- pulmonary tele-rehabilitation (PTR), home-based pulmonary rehabilitation (HPR), Control
- Where
- 7 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Chronic Kidney Disease
The Use of Low Molecular Weight Heparin in Hemodiafiltration
Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are…
- Trial name
- NCT00756145
- Testing
- At start of the session, at the inlet line, 5 minutes after the start of the session, at the inlet line, At the start of the session, at the outlet line
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Ghent
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Long COVID, Long Covid19
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT05965739
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Obesity, Metabolic Syndrome
Weight Loss Improves Renal Hemodynamics
Metabolic syndrome (MS) is a clustering of risk factors for cardiovascular disease (CVD) such as hypertension, hypertriglyceridemia, low HDL-cholesterol levels, disorders of glucose metabolism, and insulin resistance.
- Conditions
- Obesity, Metabolic Syndrome, Chronic Kidney Disease
- Trial name
- NCT01356394
- Testing
- dietary intervention
- Where
- Brazil
- Volunteers
- 58 people
- Sponsor
- Nucleus of Education Interdisciplinary Research and Treatment in Nephrology
Metabolic Syndrome, Chronic Obstructive Pulmonary Disease
Digital Metabolic Rehabilitation COPD
People with Chronic Obstructive Pulmonary Disease (COPD) are at greater risk for Metabolic syndrome (MetS). Although the management of MetS will not cure COPD, it can beneficially impact health outcomes and quality of life…
- Trial name
- NCT05806294
- Testing
- Digital Metabolic Rehabilitation
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University of Alberta
Chronic Hepatitis c
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients
The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million).
- Trial name
- NCT03687229
- Testing
- A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Critical Limb Ischemia
Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)
The investigators designed a randomized clinical trial (stem cell emergency life threatening arteriopathy or SCELTA) to compare the therapeutic efficacy of the auto-transplant of enriched circulating EPCs (ECEPCs) with…
- Trial name
- SCELTA (NCT02454231)
- Testing
- Transplantation of circulating CD14+CD34+cells, Transplantation of BM MNC
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Florence
Progressive Multiple Sclerosis
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
Primary Objective: To characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab administered by subcutaneous injection and 2 treatment courses of alemtuzumab administered by intravenous infusion in patients…
- Trial name
- SCALA (NCT02583594)
- Testing
- Acyclovir, Methylprednisolone, alemtuzumab GZ402673
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Older People, Non-Communicable Chronic Diseases
A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People
Non-Communicable Diseases (NCDs) can accelerated the aging process and increase the frailty condition The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context Recently, in Italy the…
- Trial name
- PrimaCare_P3 (NCT06224556)
- Testing
- Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program
- Where
- 4 sites in Italy
- Volunteers
- 1,216 people
- Sponsor
- Alberto Pilotto
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Health Services, Geriatric
Self Care for Older Persons in Singapore: An Intervention Study
The main aim of the project is to evaluate a self-care intervention program aimed at enhancing the ability of mildly disabled and healthy older persons in Singapore to manage their health.
- Trial name
- SCOPE (NCT01672177)
- Testing
- Chronic disease self-management training
- Where
- 12 sites in Singapore
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Diabete Mellitus, Kidney Disease
Clinical Information System Impact on Hospitalized Patients With Chronic Disease
This is a retrospective, observational study using routinely collected information collected by Alberta Health Services. The study will identify patients with chronic disease, defined by one or more of the following conditions…
- Conditions
- Diabete Mellitus, Kidney Disease, Heart Failure, Coronary Artery Disease
- Trial name
- NCT07609381
- Testing
- Clinical Information System (CIS) / Connect Care Implementation
- Where
- Canada
- Volunteers
- 124,240 people
- Sponsor
- University of Calgary
Chronic Kidney Disease, Diabetes
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress…
- Trial name
- NCT01350388
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Chronic Kidney Disease, Hyperphosphatemia
An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
Approximately 45 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 20 sites within Europe and 5-10 in Australia.
- Trial name
- NCT00681941
- Testing
- Sevelamer carbonate (Renvela®)
- Where
- 25 sites in Australia, Denmark and 3 more
- Volunteers
- 49 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT04505254
- Testing
- Acalabrutinib, Obinutuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.